1. Home
  2. RXRX
  3. RXRX News

Latest Recursion Pharmaceuticals Inc. (RXRX) News on November 23, 2025

Is Recursion Pharmaceuticals Set for Further Gains After Recent 36% Share Price Surge?
RXRX

Simply Wall St.

a month ago

Is Recursion Pharmaceuticals Set for Further Gains After Recent 36% Share Price Surge?

Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed?
RXRX

Simply Wall St.

a month ago

Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed?

AI in Biotechnology Research Report 2025: An $11.4 Billion Market by 2030, Dominated by NVIDIA, Tempus AI, Recursion Pharmaceuticals, Schrodinger, and Sophia Genetics
RXRX

GlobeNewswire

a month ago

AI in Biotechnology Research Report 2025: An $11.4 Billion Market by 2030, Dominated by NVIDIA, Tempus AI, Recursion Pharmaceuticals, Schrodinger, and Sophia Genetics

3 Growth Stocks to Invest $1,000 in Right Now
RXRX

Motley Fool

a month ago

3 Growth Stocks to Invest $1,000 in Right Now

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
RXRX

Zacks

a month ago

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights

Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event
RXRX

Insider Monkey

a month ago

Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event

Clarebout Potatoes’ staff strike over bonuses linked to JR Simplot takeover
RXRX

Just Food

2 months ago

Clarebout Potatoes’ staff strike over bonuses linked to JR Simplot takeover

World Investment Advisors Appoints Former Lincoln Executive President
RXRX

Wealth Management

2 months ago

World Investment Advisors Appoints Former Lincoln Executive President

Swoogo Acquires Amae Live to Expand Professional Services
RXRX

PR Newswire

2 months ago

Swoogo Acquires Amae Live to Expand Professional Services

Teambridge unveils new AI workforce platform, automating the future of hourly workforce management at scale
RXRX

PR Newswire

2 months ago

Teambridge unveils new AI workforce platform, automating the future of hourly workforce management at scale

Stock Market Today: Dow Jones Dips; AMD Soars On OpenAI Deal, Tesla, Palantir Rebound (Live Coverage)
RXRX

Investor's Business Daily

2 months ago

Stock Market Today: Dow Jones Dips; AMD Soars On OpenAI Deal, Tesla, Palantir Rebound (Live Coverage)

RXRX

MT Newswires

2 months ago

Western Copper and Gold Submits Environmental, Socio-Economic Effects Statement for Proposed Yukon Mine Project

Sunrise Technologies achieves the 2025-2026 Microsoft AI Business Solutions Inner Circle award
RXRX

PR Newswire

2 months ago

Sunrise Technologies achieves the 2025-2026 Microsoft AI Business Solutions Inner Circle award

RXRX

MT Newswires

2 months ago

GoodRx Expands Affordable Access to Cholesterol Drug Repatha

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
RXRX

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Evaluating Recursion After a 19% Rally Amid Renewed Interest in Biotech AI Initiatives
RXRX

Simply Wall St.

2 months ago

Evaluating Recursion After a 19% Rally Amid Renewed Interest in Biotech AI Initiatives

Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)
RXRX

Insider Monkey

2 months ago

Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)

Jim Cramer on Recursion: “I Need to See a Proof of Concept Here”
RXRX

Insider Monkey

2 months ago

Jim Cramer on Recursion: “I Need to See a Proof of Concept Here”

Where Will Recursion Pharmaceuticals Be in 5 Years?
RXRX

Motley Fool

2 months ago

Where Will Recursion Pharmaceuticals Be in 5 Years?

The Biotech Stock That's Too Risky for Most Investors
RXRX

Motley Fool

2 months ago

The Biotech Stock That's Too Risky for Most Investors

Nvidia’s $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidia’s cash being recycled?
RXRX

Fortune

2 months ago

Nvidia’s $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidia’s cash being recycled?

Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
RXRX

Simply Wall St.

2 months ago

Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?

Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
RXRX

Insider Monkey

5 months ago

Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
RXRX

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

RXRX

MT Newswires

5 months ago

Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
RXRX

Motley Fool

5 months ago

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?

Insmed surges on lung drug data; Recursion cuts staff
RXRX

BioPharma Dive

5 months ago

Insmed surges on lung drug data; Recursion cuts staff

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
RXRX

Motley Fool

5 months ago

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday

RXRX

MT Newswires

5 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

RXRX

MT Newswires

5 months ago

Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
RXRX

Insider Monkey

6 months ago

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
RXRX

GlobeNewswire

6 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?
RXRX

Zacks

6 months ago

Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
RXRX

Insider Monkey

6 months ago

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
RXRX

Zacks

6 months ago

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

Recursion to Participate in Upcoming Investor Conferences
RXRX

GlobeNewswire

6 months ago

Recursion to Participate in Upcoming Investor Conferences

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
RXRX

Zacks

6 months ago

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

3 Monster Stocks to Hold for the Next 10 Years
RXRX

Motley Fool

6 months ago

3 Monster Stocks to Hold for the Next 10 Years

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales
RXRX

Simply Wall St.

6 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
RXRX

Zacks

6 months ago

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock

Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now
RXRX

Insider Monkey

6 months ago

Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now

Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
RXRX

Motley Fool

6 months ago

Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?

2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
RXRX

Motley Fool

6 months ago

2 Top Artificial Intelligence (AI) Stocks to Buy Right Now

Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
RXRX

Motley Fool

6 months ago

Why Recursion Pharmaceuticals Stock Plummeted 24% This Week

Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43
RXRX

Simply Wall St.

7 months ago

Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43

Recursion axes drug programmes to streamline pipeline
RXRX

Pharmaceutical Technology

7 months ago

Recursion axes drug programmes to streamline pipeline

RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
RXRX

Zacks

7 months ago

RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates

Recursion to Participate in Upcoming Investor Conferences
RXRX

GlobeNewswire

7 months ago

Recursion to Participate in Upcoming Investor Conferences

RXRX

GuruFocus.com

7 months ago

Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ...

Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
RXRX

Motley Fool

7 months ago

Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results
RXRX

Simply Wall St.

7 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results

AI specialist Recursion trims pipeline in latest shakeup
RXRX

BioPharma Dive

7 months ago

AI specialist Recursion trims pipeline in latest shakeup

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
RXRX

Zacks

7 months ago

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

RXRX

MT Newswires

7 months ago

Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases

RXRX

Associated Press Finance

7 months ago

Recursion Pharmaceuticals: Q1 Earnings Snapshot

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
RXRX

GlobeNewswire

7 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

RXRX

MT Newswires

7 months ago

Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
RXRX

GlobeNewswire

7 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
RXRX

Insider Monkey

7 months ago

Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
RXRX

Zacks

7 months ago

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
RXRX

GlobeNewswire

7 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
RXRX

Zacks

7 months ago

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?

3 Monster Stocks to Hold for the Next 10 Years
RXRX

Motley Fool

7 months ago

3 Monster Stocks to Hold for the Next 10 Years

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
RXRX

GlobeNewswire

7 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know
RXRX

Zacks

7 months ago

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal
RXRX

Simply Wall St.

7 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
RXRX

Motley Fool

7 months ago

This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?

RXRX

MT Newswires

7 months ago

Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
RXRX

PR Newswire

7 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?
RXRX

Insider Monkey

7 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”
RXRX

Insider Monkey

7 months ago

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
RXRX

Zacks

7 months ago

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?
RXRX

Insider Monkey

7 months ago

Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?

Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?
RXRX

Insider Monkey

7 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?

Recursion Pharma rises, Intel & Five Below fall: Trending Tickers
RXRX

Yahoo Finance Video

7 months ago

Recursion Pharma rises, Intel & Five Below fall: Trending Tickers

Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
RXRX

Motley Fool

7 months ago

Why Recursion Pharmaceuticals Stock Is Skyrocketing Today

RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
RXRX

Zacks

7 months ago

RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
RXRX

GlobeNewswire

7 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

RXRX

MT Newswires

7 months ago

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
RXRX

GlobeNewswire

7 months ago

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes
RXRX

Simply Wall St.

8 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
RXRX

Motley Fool

8 months ago

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
RXRX

Fortune

8 months ago

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Recursion to Participate in Upcoming Investor Conference
RXRX

GlobeNewswire

8 months ago

Recursion to Participate in Upcoming Investor Conference

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
RXRX

Motley Fool

8 months ago

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
RXRX

Motley Fool

8 months ago

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?
RXRX

Insider Monkey

8 months ago

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?
RXRX

Insider Monkey

8 months ago

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
RXRX

Zacks

8 months ago

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering
RXRX

Simply Wall St.

8 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?
RXRX

Insider Monkey

8 months ago

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
RXRX

GlobeNewswire

8 months ago

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Big tech meets biotech: Recursion and the AI gold rush in pharma
RXRX

Pharmaceutical Technology

8 months ago

Big tech meets biotech: Recursion and the AI gold rush in pharma

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’
RXRX

Insider Monkey

8 months ago

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’

Why Recursion Pharmaceuticals Stock Is Sinking Today
RXRX

Motley Fool

8 months ago

Why Recursion Pharmaceuticals Stock Is Sinking Today

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
RXRX

Motley Fool

9 months ago

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
RXRX

Motley Fool

9 months ago

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

This Biotech Stock Could Be the Best Investment of the Decade
RXRX

Motley Fool

9 months ago

This Biotech Stock Could Be the Best Investment of the Decade

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
RXRX

Motley Fool

9 months ago

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts
RXRX

Simply Wall St.

9 months ago

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Share on Social Networks: